Gregory A. Vidal

3.0k total citations
76 papers, 1.3k citations indexed

About

Gregory A. Vidal is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Gregory A. Vidal has authored 76 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 20 papers in Cancer Research. Recurrent topics in Gregory A. Vidal's work include Advanced Breast Cancer Therapies (17 papers), Global Cancer Incidence and Screening (10 papers) and Medication Adherence and Compliance (10 papers). Gregory A. Vidal is often cited by papers focused on Advanced Breast Cancer Therapies (17 papers), Global Cancer Incidence and Screening (10 papers) and Medication Adherence and Compliance (10 papers). Gregory A. Vidal collaborates with scholars based in United States, United Kingdom and Spain. Gregory A. Vidal's co-authors include Luis Marrero, Frank E. Jones, Anjali Naresh, Lee S. Schwartzberg, Christopher C. Williams, Barbara S. Beckman, Matthew E. Burow, Ilana Graetz, Janeane N. Anderson and Athena Starlard‐Davenport and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Gregory A. Vidal

65 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gregory A. Vidal United States	17	784	514	198	190	179	76	1.3k
Tessa Cigler United States	20	633 0.8×	261 0.5×	110 0.6×	176 0.9×	189 1.1×	54	1.2k
Eric Steiner Germany	18	638 0.8×	564 1.1×	149 0.8×	267 1.4×	346 1.9×	35	1.7k
Akemi Kataoka Japan	21	680 0.9×	425 0.8×	99 0.5×	212 1.1×	447 2.5×	55	1.2k
G von Minckwitz Germany	15	604 0.8×	259 0.5×	159 0.8×	92 0.5×	460 2.6×	48	1.0k
Leonard Reyno United States	22	694 0.9×	332 0.6×	196 1.0×	503 2.6×	214 1.2×	46	1.6k
Jessica St. Louis United States	12	729 0.9×	499 1.0×	136 0.7×	189 1.0×	476 2.7×	24	1.5k
Kenneth Villman Sweden	19	678 0.9×	323 0.6×	158 0.8×	140 0.7×	318 1.8×	33	1.1k
Sophie Dessureault United States	21	757 1.0×	600 1.2×	97 0.5×	113 0.6×	358 2.0×	70	1.8k
Michael Hubalek Austria	26	1.1k 1.4×	650 1.3×	246 1.2×	389 2.0×	517 2.9×	74	2.0k
Jo Anne Zujewski United States	14	1.1k 1.4×	216 0.4×	380 1.9×	233 1.2×	461 2.6×	23	1.3k

Countries citing papers authored by Gregory A. Vidal

Since Specialization

Citations

This map shows the geographic impact of Gregory A. Vidal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory A. Vidal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory A. Vidal more than expected).

Fields of papers citing papers by Gregory A. Vidal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory A. Vidal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory A. Vidal. The network helps show where Gregory A. Vidal may publish in the future.

Co-authorship network of co-authors of Gregory A. Vidal

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory A. Vidal. A scholar is included among the top collaborators of Gregory A. Vidal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory A. Vidal. Gregory A. Vidal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mahtani, Reshma, et al.. (2025). Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Early Breast Cancer Treatment and Outcomes by Risk of Recurrence: A Retrospective US Electronic Health Records Study. Cancers. 17(11). 1848–1848.

Mayer, Erik N., M.V. Martín, Gregory A. Vidal, et al.. (2025). LBA16 Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial. Annals of Oncology. 36. S1561–S1562. 2 indexed citations

Hu, Xin, Rebecca A. Krukowski, Teresa M. Waters, et al.. (2025). COVID ‐19‐Related Financial Hardship and Adherence to Adjuvant Endocrine Therapy Among Women With Early‐Stage Breast Cancer. Health Services Research. 61(2). e14658–e14658.

Swain, Sandra M., Shannon L. Puhalla, Patricia A. Ganz, et al.. (2024). A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009.. Journal of Clinical Oncology. 42(16_suppl). TPS612–TPS612. 3 indexed citations

Vidal, Gregory A., Neha Jain, Aaron Fisher, et al.. (2024). Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non–Small-Cell Lung Cancer Treated in the US Community Setting. JCO Oncology Practice. 20(3). 370–377. 3 indexed citations

John, Elizabeth S., et al.. (2024). An Open-Label Phase II Trial NCT03812393 to Evaluate the Efficacy and Safety of Neoadjuvant Neratinib Followed by Weekly Paclitaxel and Carboplatin Plus Neratinib in Early-Stage Triple-Negative Breast Cancer (TNBC) Patients Who Exhibit Enhanced HER2 Signaling by Live Cell HER2 Signaling Transduction Analysis (FACT-2). 4(Supplement 1). 1 indexed citations

Cao, Xueyuan, et al.. (2022). Characterization of the Metabolome of Breast Tissues from Non-Hispanic Black and Non-Hispanic White Women Reveals Correlations between Microbial Dysbiosis and Enhanced Lipid Metabolism Pathways in Triple-Negative Breast Tumors. Cancers. 14(17). 4075–4075. 9 indexed citations

Hu, Xin, Cameron M. Kaplan, Michelle Y. Martin, et al.. (2022). Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. 32(2). 167–174. 6 indexed citations

Saltman, David L., Matthew G. Varga, Nicole S. Croteau, et al.. (2022). 27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study. Clinical Lung Cancer. 24(2). 137–144. 2 indexed citations

10.

Vanderwalde, Ari M., Axel Grothey, Daniel A. Vaena, et al.. (2020). Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. Journal of Personalized Medicine. 10(4). 252–252. 16 indexed citations

11.

Schwartzberg, Lee S. & Gregory A. Vidal. (2020). Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2–Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations. Clinical Breast Cancer. 20(4). e439–e449. 15 indexed citations

12.

Anderson, Janeane N., Rebecca A. Krukowski, J. Carolyn Graff, et al.. (2020). THRIVE intervention development: using participatory action research principles to guide a mHealth app-based intervention to improve oncology care. PubMed. 5. 5–5. 9 indexed citations

13.

Jain, Amit, Amina Chaudhry, Michael P. Berry, et al.. (2020). Unusual recurrent metastasizing benign breast papilloma: a case report. Journal of Medical Case Reports. 14(1). 33–33. 1 indexed citations

14.

McGregor, Bradley A., Gregory A. Vidal, Sumit Shah, James Mitchell, & Andrew Hendifar. (2020). Remote Oncology Care: Review of Current Technology and Future Directions. Cureus. 12(8). e10156–e10156. 18 indexed citations

15.

Heeke, Arielle L., Joanne Xiu, Andrew Elliott, et al.. (2020). Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. Breast Cancer Research and Treatment. 184(2). 265–275. 19 indexed citations

16.

Vidal, Gregory A., Zoran Bursac, Gustavo A. Miranda‐Carboni, Shelley I. White‐Means, & Athena Starlard‐Davenport. (2017). Racial disparities in survival outcomes by breast tumor subtype among African American women in Memphis, Tennessee. Cancer Medicine. 6(7). 1776–1786. 23 indexed citations

17.

Schwartzberg, Lee S., et al.. (2017). Selective Androgen Receptor Modulator in a Patient With Hormone-Positive Metastatic Breast Cancer. Journal of the National Comprehensive Cancer Network. 15(3). 284–287. 5 indexed citations

18.

Naresh, Anjali, Weiwen Long, Gregory A. Vidal, et al.. (2006). The ERBB4/HER4 Intracellular Domain 4ICD Is a BH3-Only Protein Promoting Apoptosis of Breast Cancer Cells. Cancer Research. 66(12). 6412–6420. 172 indexed citations

19.

Vidal, Gregory A., Anjali Naresh, Luis Marrero, & Frank E. Jones. (2005). Presenilin-dependent γ-Secretase Processing Regulates Multiple ERBB4/HER4 Activities. Journal of Biological Chemistry. 280(20). 19777–19783. 109 indexed citations

20.

Vidal, Gregory A., et al.. (2004). Genomic and Phylogenic Comparisons of the α -Globin and β -Globin Intergenic Sequences between Zebra Fish ( Danio rerio ) and Six Closely Related Cyprinindae Species. DNA and Cell Biology. 23(5). 325–334. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact